Do Evoke Pharma Inc. (EVOK) beta value of 1.41 signposts another twist?

At the end of the latest market close, Evoke Pharma Inc. (EVOK) was valued at $2.73. In that particular session, Stock kicked-off at the price of $2.896 while reaching the peak value of $3.68 and lowest value recorded on the day was $2.70. The stock current value is $2.95.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Recently in News on January 14, 2021, Evoke Pharma Announces Pricing of Public Offering of Common Stock. Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that it has priced an underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $2.50 per share. Gross proceeds, before underwriting discounts and commissions and estimated offering costs, are expected to be $12.5 million. Evoke has granted the underwriter a 45-day option to purchase up to 750,000 additional shares of its common stock. The offering is expected to close on or about January 19, 2021, subject to satisfaction of customary closing conditions. You can read further details here

5 Stocks to make up the PERFECT 2021 gold portfolio

Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.

Click here to download your free report right away


Evoke Pharma Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $3.68 on 01/13/21, with the lowest value was $2.53 for the same time period, recorded on 01/11/21.

Evoke Pharma Inc. (EVOK) full year performance was 85.71%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Evoke Pharma Inc. shares are logging -51.34% during the 52-week period from high price, and 273.42% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.79 and $6.06.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1248391 for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Evoke Pharma Inc. (EVOK) recorded performance in the market was 5.81%, having the revenues showcasing -44.06% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 73.41M, as it employees total of 5 workers.

Evoke Pharma Inc. (EVOK) in the eye of market guru’s

During the last month, 0 analysts gave the Evoke Pharma Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on, the moving average of the company in the 100-day period was set at 3.84, with a change in the price was noted -1.75. In a similar fashion, Evoke Pharma Inc. posted a movement of -37.05% for the period of last 100 days, recording 277,363 in trading volumes.

Evoke Pharma Inc. (EVOK): Stocks Technical analysis and Trends

Raw Stochastic average of Evoke Pharma Inc. in the period of last 50 days is set at 35.30%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 39.94%. In the last 20 days, the company’s Stochastic %K was 29.02% and its Stochastic %D was recorded 22.51%.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

If we look into the earlier routines of Evoke Pharma Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 5.81%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -23.31%, alongside a boost of 85.71% for the period of the last 12 months. The shares increased approximately by 1.11% in the 7-day charts and went up by -5.86% in the period of the last 30 days. Common stock shares were lifted by -44.06% during last recorded quarter.

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free


Please enter your comment!
Please enter your name here